A Ni(OH)₂–CoS₂ nanowire array on a carbon cloth acts as a 3D catalyst electrode for a hydrogen evolution reaction, with only 99 mV overpotential to drive 20 mA cm⁻² in 1.0 M KOH, 100 mV less than that of a CoS₂ nanoarray.

The major drawbacks of traditional RNA cancer therapies include low cellular uptake in vitro or in vivo, instability of in vivo circulation, nonspecific bio-distribution, and lack of targeting ability, which result in poor silencing efficiency. Herein, we developed a novel RNA-triple-helix hydrogel for the treatment of triple negative breast cancers (TNBCs) by incorporating RNA-triple-helix and siRNA duplexes of CXCR4 into the same RNA nanoparticles with no synthetic polycationic reagents added. The RNA-triple-helix consists of one tumour suppressor miRNA (miRNA-205) and one oncomiR inhibitor (miRNA-221), both of which showed an outstanding effect in synergistically abrogating tumours. The siRNA duplexes of CXCR4 were embedded into the RNA hydrogel to block breast cancer metastasis and conjugation of the LXL-DNA aptamer (apt-DNA-Chol) is an effective target DNA sequence for MDA-MB-231 cells. The self-assembly of the RNA-triple-helix hydrogel exhibited high selectivity of in vitro and in vivo absorption and controlling miRNA expression when compared to free miRNA and RNA transcripts. The well-developed gene delivery system provided a potential treatment with high specificity and selectivity toward TNBCs. This strategy can be implemented in triplex-helix hydrogel design to form novel miRNA combinations to treat various human cancers.

This review gives an in-depth understanding of structure–performance relationships achieved from fused-ring based nonfullerene acceptors with perpendicular side-chains.

A surface plasmon resonance (SPR) detection system based on a hybridization chain reaction (HCR) was developed for amplified detection of DNA and small molecules with high sensitivity. This methodology is capable of detecting the target in complicated biological samples and can be further extended to the detection of other proteins or biomarkers.